Virpax Pharmaceuticals CEO Anthony Mack's 2021 pay jumps 25% to $758K
Virpax Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: June 15, 2022
Virpax Pharmaceuticals reported fiscal year 2021 executive compensation information on June 15, 2022.
In 2021, three executives at Virpax Pharmaceuticals received on average a compensation package of $492K, a 40% increase compared to previous year.
Average pay of disclosed executives at Virpax Pharmaceuticals
Anthony Mack, Chief Executive Officer, received $758K in total, which increased by 25% compared to 2020. 49% of Mack's compensation, or $375K, was in salary. Mack also received $225K in bonus and $158K in option awards.
Christopher Chipman, Chief Financial Officer, received a compensation package of $415K, which increased by 50% compared to previous year. 57% of the compensation package, or $236K, was in salary.
Jeffrey Gudin, Chief Medical Officer, earned $303K in 2021, a 75% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on June 15, 2022.